2025 Q4 -tulosraportti
Vain PDF
53 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 228 | - | - | ||
| 10 157 | - | - | ||
| 2 539 | - | - | ||
| 1 439 | - | - | ||
| 250 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenComment from Dr Harin Padma-Nathan If you were to convey a single key message to investors trying to understand LIB-01's potential – what would it be? – LIB-01 offers a new mechanism of action, meaning that patients who have not responded to other treatments may respond to this one. We have seen a broad effect regardless of the baseline severity of erectile dysfunction. – But what will appeal most to patients is this: I can regain spontaneity in my sexual life, because I can take the medicine for three days and the functional effect extends over one to two months – something unparalleled among today's available medicines. – The combination of good efficacy, good tolerability, absence of contraindications, and a unique pharmacodynamic profile that enables spontaneity means that LIB-01 has the potential to become a first-line treatment. (taken from the annual report for 2025 page 13) https://www.dicotpharma.com/mekanismen-ar-unik-och-genial/ About Dr Harin Padma-Nathan; Licensed physician and urologist, has held a professorship in clinical urology at the Keck School of Medicine at the University of Southern California and has received the American Urological Association's scholarship. Dr Padma-Nathan is active in California, USA. Dr Padma-Nathan has been the principal investigator in over 110 clinical trials, including the development programs for Viagra and Cialis. He has published frequently, for example, three highly acclaimed articles in the New England Journal of Medicine on Viagra, MUSE, and Caverject. The Viagra article from 1998 is still the most cited in urology. ”Mekanismen är unik och genial” - Dicot Pharma ”Mekanismen är unik och genial” - Dicot Pharma Dr Harin Padma Nathan has been involved in driving the development of drugs for erectile dysfunction for over 40 years. In an interview in Dicot Pharma's annual report for 2025, he explains why LIB-01 has piqued his interest. www.dicotpharma.com
·3 päivää sittenThe strongest are the clinical signals. The report states an 8.5 point improvement on IIEF-EF at week 4 and 7.5 points at week 8 in the relevant patient group, where the company states that ≥5 points are clinically relevant. The effect is thus described not only as statistically interesting but also as clinically meaningful, and furthermore with an unusually long duration for the area. This is probably the single most important positive data point in the report. Another positive signal is the differentiation. The company emphasizes that LIB-01 acts via nervous and vascular structures as well as the melanocortin system, which distinguishes the candidate from current treatments. If this holds in larger studies, it strengthens both commercial positioning and the ability to help patients who do not get sufficient effect from current preparations. The report also mentions potential in other indication areas. The patent aspect is also positive. In November, a new patent application was filed based on the documented long-acting effect, with the explicit purpose of strengthening and extending the intellectual property protection around LIB-01. For a biotech company in this phase, every strengthening of the IP barrier is important, especially when it is linked to clinically observed effect. Another good signal is that the project appears to have moved from “story” to more concrete execution ahead of the next study. The company signed a CRO agreement in December for preparations for phase 2b, and after the end of the fiscal year, it was announced that the tablet formulation had been successfully developed and that manufacturing of active substance and placebo for phase 2b had started. This at least reduces some of the implementation risk ahead of the next value-driving step. There are also signs of increased external interest. Dicot was included in the MSCI Global Micro Cap Index, which according to the report reflects investability based on, among other things, market capitalization, liquidity, and transparency. The company also highlights that Oppenheimer has pointed out LIB-01 as particularly interesting and that Dicot has been invited to several investor presentations, including an invitation-based conference after the turn of the year. It is not the same as a partnership agreement, but it is still a positive signal of increased visibility towards institutional capital. Financially, the picture is mixed but not weak. The clearly positive aspect is that TO 6 was subscribed to 96 percent and contributed 43.8 MSEK before issue costs, and that cash at year-end was 69.2 MSEK and solidity was 85.8 percent. This shows that the company still has a relatively strong balance sheet for its phase.
·31.3.Sold out now?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
53 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenComment from Dr Harin Padma-Nathan If you were to convey a single key message to investors trying to understand LIB-01's potential – what would it be? – LIB-01 offers a new mechanism of action, meaning that patients who have not responded to other treatments may respond to this one. We have seen a broad effect regardless of the baseline severity of erectile dysfunction. – But what will appeal most to patients is this: I can regain spontaneity in my sexual life, because I can take the medicine for three days and the functional effect extends over one to two months – something unparalleled among today's available medicines. – The combination of good efficacy, good tolerability, absence of contraindications, and a unique pharmacodynamic profile that enables spontaneity means that LIB-01 has the potential to become a first-line treatment. (taken from the annual report for 2025 page 13) https://www.dicotpharma.com/mekanismen-ar-unik-och-genial/ About Dr Harin Padma-Nathan; Licensed physician and urologist, has held a professorship in clinical urology at the Keck School of Medicine at the University of Southern California and has received the American Urological Association's scholarship. Dr Padma-Nathan is active in California, USA. Dr Padma-Nathan has been the principal investigator in over 110 clinical trials, including the development programs for Viagra and Cialis. He has published frequently, for example, three highly acclaimed articles in the New England Journal of Medicine on Viagra, MUSE, and Caverject. The Viagra article from 1998 is still the most cited in urology. ”Mekanismen är unik och genial” - Dicot Pharma ”Mekanismen är unik och genial” - Dicot Pharma Dr Harin Padma Nathan has been involved in driving the development of drugs for erectile dysfunction for over 40 years. In an interview in Dicot Pharma's annual report for 2025, he explains why LIB-01 has piqued his interest. www.dicotpharma.com
- ·3 päivää sittenThe strongest are the clinical signals. The report states an 8.5 point improvement on IIEF-EF at week 4 and 7.5 points at week 8 in the relevant patient group, where the company states that ≥5 points are clinically relevant. The effect is thus described not only as statistically interesting but also as clinically meaningful, and furthermore with an unusually long duration for the area. This is probably the single most important positive data point in the report. Another positive signal is the differentiation. The company emphasizes that LIB-01 acts via nervous and vascular structures as well as the melanocortin system, which distinguishes the candidate from current treatments. If this holds in larger studies, it strengthens both commercial positioning and the ability to help patients who do not get sufficient effect from current preparations. The report also mentions potential in other indication areas. The patent aspect is also positive. In November, a new patent application was filed based on the documented long-acting effect, with the explicit purpose of strengthening and extending the intellectual property protection around LIB-01. For a biotech company in this phase, every strengthening of the IP barrier is important, especially when it is linked to clinically observed effect. Another good signal is that the project appears to have moved from “story” to more concrete execution ahead of the next study. The company signed a CRO agreement in December for preparations for phase 2b, and after the end of the fiscal year, it was announced that the tablet formulation had been successfully developed and that manufacturing of active substance and placebo for phase 2b had started. This at least reduces some of the implementation risk ahead of the next value-driving step. There are also signs of increased external interest. Dicot was included in the MSCI Global Micro Cap Index, which according to the report reflects investability based on, among other things, market capitalization, liquidity, and transparency. The company also highlights that Oppenheimer has pointed out LIB-01 as particularly interesting and that Dicot has been invited to several investor presentations, including an invitation-based conference after the turn of the year. It is not the same as a partnership agreement, but it is still a positive signal of increased visibility towards institutional capital. Financially, the picture is mixed but not weak. The clearly positive aspect is that TO 6 was subscribed to 96 percent and contributed 43.8 MSEK before issue costs, and that cash at year-end was 69.2 MSEK and solidity was 85.8 percent. This shows that the company still has a relatively strong balance sheet for its phase.
- ·31.3.Sold out now?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 228 | - | - | ||
| 10 157 | - | - | ||
| 2 539 | - | - | ||
| 1 439 | - | - | ||
| 250 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
53 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenComment from Dr Harin Padma-Nathan If you were to convey a single key message to investors trying to understand LIB-01's potential – what would it be? – LIB-01 offers a new mechanism of action, meaning that patients who have not responded to other treatments may respond to this one. We have seen a broad effect regardless of the baseline severity of erectile dysfunction. – But what will appeal most to patients is this: I can regain spontaneity in my sexual life, because I can take the medicine for three days and the functional effect extends over one to two months – something unparalleled among today's available medicines. – The combination of good efficacy, good tolerability, absence of contraindications, and a unique pharmacodynamic profile that enables spontaneity means that LIB-01 has the potential to become a first-line treatment. (taken from the annual report for 2025 page 13) https://www.dicotpharma.com/mekanismen-ar-unik-och-genial/ About Dr Harin Padma-Nathan; Licensed physician and urologist, has held a professorship in clinical urology at the Keck School of Medicine at the University of Southern California and has received the American Urological Association's scholarship. Dr Padma-Nathan is active in California, USA. Dr Padma-Nathan has been the principal investigator in over 110 clinical trials, including the development programs for Viagra and Cialis. He has published frequently, for example, three highly acclaimed articles in the New England Journal of Medicine on Viagra, MUSE, and Caverject. The Viagra article from 1998 is still the most cited in urology. ”Mekanismen är unik och genial” - Dicot Pharma ”Mekanismen är unik och genial” - Dicot Pharma Dr Harin Padma Nathan has been involved in driving the development of drugs for erectile dysfunction for over 40 years. In an interview in Dicot Pharma's annual report for 2025, he explains why LIB-01 has piqued his interest. www.dicotpharma.com
- ·3 päivää sittenThe strongest are the clinical signals. The report states an 8.5 point improvement on IIEF-EF at week 4 and 7.5 points at week 8 in the relevant patient group, where the company states that ≥5 points are clinically relevant. The effect is thus described not only as statistically interesting but also as clinically meaningful, and furthermore with an unusually long duration for the area. This is probably the single most important positive data point in the report. Another positive signal is the differentiation. The company emphasizes that LIB-01 acts via nervous and vascular structures as well as the melanocortin system, which distinguishes the candidate from current treatments. If this holds in larger studies, it strengthens both commercial positioning and the ability to help patients who do not get sufficient effect from current preparations. The report also mentions potential in other indication areas. The patent aspect is also positive. In November, a new patent application was filed based on the documented long-acting effect, with the explicit purpose of strengthening and extending the intellectual property protection around LIB-01. For a biotech company in this phase, every strengthening of the IP barrier is important, especially when it is linked to clinically observed effect. Another good signal is that the project appears to have moved from “story” to more concrete execution ahead of the next study. The company signed a CRO agreement in December for preparations for phase 2b, and after the end of the fiscal year, it was announced that the tablet formulation had been successfully developed and that manufacturing of active substance and placebo for phase 2b had started. This at least reduces some of the implementation risk ahead of the next value-driving step. There are also signs of increased external interest. Dicot was included in the MSCI Global Micro Cap Index, which according to the report reflects investability based on, among other things, market capitalization, liquidity, and transparency. The company also highlights that Oppenheimer has pointed out LIB-01 as particularly interesting and that Dicot has been invited to several investor presentations, including an invitation-based conference after the turn of the year. It is not the same as a partnership agreement, but it is still a positive signal of increased visibility towards institutional capital. Financially, the picture is mixed but not weak. The clearly positive aspect is that TO 6 was subscribed to 96 percent and contributed 43.8 MSEK before issue costs, and that cash at year-end was 69.2 MSEK and solidity was 85.8 percent. This shows that the company still has a relatively strong balance sheet for its phase.
- ·31.3.Sold out now?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 228 | - | - | ||
| 10 157 | - | - | ||
| 2 539 | - | - | ||
| 1 439 | - | - | ||
| 250 | - | - |
Välittäjätilasto
Dataa ei löytynyt